Arcutis initiates phase III clinical trial of topical roflumilast cream (ARQ 151) as a potential treatment for atopic dermatitis in pediatric patients between the ages of two and five years.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest